← Back to Search

Taxane

Tesetaxel once every 3 weeks for Breast Cancer

Phase 2
Waitlist Available
Led By Andrew D Seidman, MD
Research Sponsored by Genta Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months from date of first dose of study medication for last patient enrolled
Awards & highlights

Study Summary

The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer. Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months from date of first dose of study medication for last patient enrolled
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months from date of first dose of study medication for last patient enrolled for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Response rate (revised RECIST)
Secondary outcome measures
Adverse events
Disease control rate
Durable response rate
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Tesetaxel once weeklyExperimental Treatment1 Intervention
Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
Group II: Tesetaxel once every 3 weeksExperimental Treatment1 Intervention
Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months

Find a Location

Who is running the clinical trial?

Genta IncorporatedLead Sponsor
30 Previous Clinical Trials
1,589 Total Patients Enrolled
Andrew D Seidman, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
213 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
2010. "Tesetaxel as First-line Therapy for Metastatic Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01221870.
All > Metastatic Breast Cancer
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top